UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

2020 international consensus on ANCA testing beyond systemic vasculitis

Moiseev, S; Tervaert, JWC; Arimura, Y; Bogdanos, DP; Csernok, E; Damoiseaux, J; Ferrante, M; ... Bossuyt, X; + view all (2020) 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews , 19 (9) , Article 102618. 10.1016/j.autrev.2020.102618. Green open access

[thumbnail of Salama_ANCA-testing-consensus22.12.pdf]
Preview
Text
Salama_ANCA-testing-consensus22.12.pdf - Accepted Version

Download (463kB) | Preview

Abstract

This document follows up on a 2017 revised international consensus on anti-neutrophil cytoplasm antibodies (ANCA) testing in granulomatosis with polyangiitis and microscopic polyangiitis and focuses on the clinical and diagnostic value of ANCA detection in patients with connective tissue diseases, idiopathic interstitial pneumonia, autoimmune liver diseases, inflammatory bowel diseases, anti-glomerular basement membrane (GBM) disease, infections, malignancy, and during drug treatment. Current evidence suggests that in certain settings beyond systemic vasculitis, ANCA may have clinical, pathogenic and/or diagnostic relevance. Antigen-specific ANCA targeting proteinase-3 and myeloperoxidase should be tested by solid phase immunoassays in any patient with clinical features suggesting ANCA-associated vasculitis and in all patients with anti-GBM disease, idiopathic interstitial pneumonia, and infective endocarditis associated with nephritis, whereas in patients with other aforementioned disorders routine ANCA testing is not recommended. Among patients with autoimmune liver diseases or inflammatory bowel diseases, ANCA testing may be justified in patients with suspected autoimmune hepatitis type 1 who do not have conventional autoantibodies or in case of diagnostic uncertainty to discriminate ulcerative colitis from Crohn’s disease. In these cases, ANCA should be tested by indirect immunofluorescence as the target antigens are not yet well characterized. Many questions concerning the optimal use of ANCA testing in patients without ANCA-associated vasculitis remain to be answered.

Type: Article
Title: 2020 international consensus on ANCA testing beyond systemic vasculitis
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.autrev.2020.102618
Publisher version: https://doi.org/10.1016/j.autrev.2020.102618
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10112198
Downloads since deposit
374Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item